Auris Medical – About the Company
Auris Medical is a development-stage biotechnology company focused on the development of pharmacological treatments for inner ear disorders. The Company’s lead candidate is an NMDA antagonist, AM-101, for inner ear tinnitus patients that has generated promising data in a Phase II trial. Auris recently initiated two Phase III trials evaluating AM-101 in this indication and expects to report topline data in the first quarter of 2016. The Company also has a drug cndidate, AM-111, for the treatment of acute inner ear hearing loss. Auris reported positive Phase II data in this indication and plans to launch a Phase III trial in the first quarter of 2015. Data from this trial are expected in the first quarter of 2017. Both of these indications represent large unmet medical needs with no approved therapies currently available. With both drug candidates in or nearing Phase III trials, Auris Medical is well-positioned to capitalize on this opportunity.